Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Solabegron

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Velicept Announces Positive Top-Line Ph2b Results for Solabegron OAB
    Velicept Announces Positive Top-Line Ph2b Results for Solabegron OAB

    28 Mar 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190328005483/en/Velicept-Therapeutics-Announces-Positive-Top-Line-Phase-2b/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==

    BUSINESSWIRE
    28 Mar 2019
    Share Share
    Overactive bladder biotech Urovant Sciences sets terms for $150 million IPO
    Overactive bladder biotech Urovant Sciences sets terms for $150 million IPO

    17 Sep 2018

    // NASDAQ

    https://www.nasdaq.com/article/overactive-bladder-biotech-urovant-sciences-sets-terms-for-150-million-ipo-cm1023564

    NASDAQ
    17 Sep 2018
    Share Share